



(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 325 765 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
09.07.2003 Bulletin 2003/28

(51) Int Cl.7: **A61P 11/00**, **A61K 31/58**,
A61K 31/167

(21) Application number: **03003950.7**

(22) Date of filing: **01.03.2000**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

Designated Extension States:
RO SI

(30) Priority: **03.03.1999 GB 9904919**

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
00910739.2 / 1 156 790

(71) Applicants:

- **Novartis AG**
4056 Basel (CH)
- **Novartis Pharma GmbH**
1235 Vienna (AT)

(72) Inventors:

- **Hassan, Ian Francis**
Morris Plains, NJ 07950 (US)
- **Clarke, Jeremy Guy**
Bath, BA1 2ST (GB)
- **Danahay, Henry Luke**
Horsham, West Sussex RH13 5HJ (GB)

(74) Representative: **Gros, Florent et al**
Novartis AG
Corporate Intellectual Property,
Patent & Trademark Department CH
4002 Basel (CH)

Remarks:

This application was filed on 22 - 02 - 2003 as a
divisional application to the application mentioned
under INID code 62.

(54) **Combinations of Formoterol and Mometasone Furoate for Asthma**

(57) A medicament containing, separately or together, (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or a solvate of the salt and (B) mometasone furoate, for simultaneous, sequen-

tial or separate administration in the treatment of an inflammatory or obstructive airways disease.

EP 1 325 765 A1

Best Available Copy

Description

[0001] This invention relates to combinations of a beta-2 agonist and a steroid and their use for the treatment of inflammatory or obstructive airways diseases.

5 [0002] Formoterol, N-[2-hydroxy-5-(1-hydroxy-2-((2-(4-methoxyphenyl)-1-methylethyl)amino)-ethyl)phenyl]formamide, particularly in the form of its fumarate salt, is a bronchodilator used in the treatment of inflammatory or obstructive airways diseases. Mometasone furoate, (11 β , 16 α)-9,21-dichloro-17-((2-furanylcarbonyloxy)-11-hydroxy-16-methylpregna-1, 4-diene-3,20-dione, alternatively designated 9 α ,21-dichloro-16 α -methyl-1,4-pregnadiene-11 β ,17 α -diol-3,20-dione 17-(2'-furoate), is a topical anti-inflammatory corticosteroid which is described in US4472393.

10 [0003] It has now surprisingly been found that a significant unexpected therapeutic benefit, particularly a synergistic therapeutic benefit, in the treatment of inflammatory or obstructive airways diseases can be obtained by combination therapy using formoterol, in free form or in the form of a salt or solvate thereof, and mometasone furoate. For instance, it is possible using this combination therapy to reduce the dosages of mometasone furoate or formoterol required for a given therapeutic effect considerably compared with those required using treatment with mometasone furoate or formoterol alone, thereby minimising possibly undesirable side effects. In particular, it has been found that these combinations, particularly as compositions containing formoterol and mometasone furoate, induce an anti-inflammatory activity which is significantly greater than that induced by formoterol or mometasone furoate alone and that the amount of mometasone furoate needed for a given anti-inflammatory effect may be significantly reduced when used in admixture with formoterol, thereby reducing the risk of undesirable side effects from the repeated exposure to the steroid involved in the treatment of inflammatory or obstructive airways diseases.

20 [0004] Furthermore, using the combination therapy of the invention, particularly using compositions containing formoterol and mometasone furoate, medicaments which have a rapid onset of action and a long duration of action may be prepared. Moreover, using such combination therapy, medicaments which result in a significant improvement in lung function may be prepared. In another aspect, using the combination therapy of the invention, medicaments which provide improved control of obstructive or inflammatory airways diseases, or a reduction in exacerbations of such diseases, may be prepared. In a further aspect, using compositions of the invention, medicaments which can be used on demand in rescue treatment of obstructive or inflammatory airways diseases, or which reduce or eliminate the need for treatment with short-acting rescue medicaments such as salbutamol or terbutaline, may be prepared; thus medicaments based on compositions of the invention facilitate the treatment of an obstructive or inflammatory airways disease with a single medicament.

30 [0005] In one aspect, the present invention provides a medicament containing, separately or together, (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or a solvate of said salt and (B) mometasone furoate, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.

35 [0006] In another aspect, the present invention provides a method of treating an inflammatory or obstructive airways disease which comprises administering to a subject in need of such treatment effective amounts of (A) as hereinbefore defined and (B) as hereinbefore defined.

40 [0007] In a further aspect, the present invention provides a pharmaceutical composition comprising a mixture of effective amounts of (A) as hereinbefore defined and (B) as hereinbefore defined, optionally together with a pharmaceutically acceptable carrier.

[0008] The present invention also provides (A) and (B) as hereinbefore defined for use in combination therapy by simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.

45 [0009] The invention further provides the use of (A) as hereinbefore defined or (B) as hereinbefore defined in the preparation of a medicament for combination therapy by simultaneous, sequential or separate administration of (A) and (B) in the treatment of an inflammatory or obstructive airways disease.

[0010] In a yet further aspect, the present invention provides a pharmaceutical composition for use in the treatment of an inflammatory or obstructive airways disease comprising (A) and (B) as hereinbefore defined.

50 [0011] The present invention still further provides the use of (A) and (B) as hereinbefore defined for the preparation of a medicament for combination therapy by simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.

[0012] Pharmaceutically acceptable salts of formoterol include, for example, salts of inorganic acids such as hydrochloric, hydrobromic, sulfuric and phosphoric acids, and organic acids such as fumaric, maleic, acetic, lactic, citric, tartaric, ascorbic, succinic, glutaric, gluconic, tricarballic, oleic, benzoic, p-methoxybenzoic, salicylic, o- and p-hydroxybenzoic, p-chlorobenzoic, methanesulfonic, p-toluenesulfonic and 3-hydroxy-2-naphthalene carboxylic acids.

55 [0013] Component (A) may be in any isomeric form or mixture of isomeric forms, for example a pure enantiomer, a mixture of enantiomers, a racemate or a mixture thereof. It may be in the form of a solvate, for example a hydrate, thereof, for example as described in US3994974 or US5684199, and may be present in a particular crystalline form, for example as described in WO95/05805. Preferably, component (A) is formoterol fumarate, especially in the form of

the dihydrate.

[0014] Administration of the medicament or pharmaceutical composition as hereinbefore described, i.e. with (A) and (B) in admixture or separate, is preferably by inhalation, i.e. (A) and (B) or the mixture thereof are in inhalable form. The inhalable form of the medicament i.e. of (A) and/or (B) may be, for example, an atomizable composition such as an aerosol comprising the active ingredient, i.e. (A) and (B) separately or in admixture, in solution or dispersion in a propellant, or a nebulizable composition comprising a dispersion of the active ingredient in an aqueous, organic or aqueous/organic medium. For example, the inhalable form of the medicament may be an aerosol comprising a mixture of (A) and (B) in solution or dispersion in a propellant, or a combination of an aerosol containing (A) in solution or dispersion in a propellant with an aerosol containing (B) in solution or dispersion in a propellant. In another example, the inhalable form is a nebulizable composition comprising a dispersion of (A) and (B) in an aqueous, organic or aqueous/organic medium, or a combination of a dispersion of (A) in such a medium with a dispersion of (B) in such a medium.

[0015] An aerosol composition suitable for use as the inhalable form of the medicament may comprise the active ingredient in solution or dispersion in a propellant, which may be chosen from any of the propellants known in the art. Suitable such propellants include hydrocarbons such as n-propane, n-butane or isobutane or mixtures of two or more such hydrocarbons, and halogen-substituted hydrocarbons, for example fluorine-substituted methanes, ethanes, propanes, butanes, cyclopropanes or cyclobutanes, particularly 1,1,1,2-tetrafluoroethane (HFA134a) and 1,1,1,2,3,3,3-heptafluoropropane (HFA227), or mixtures of two or more such halogen-substituted hydrocarbons. Where the active ingredient is present in suspension in the propellant, i.e. where it is present in particulate form dispersed in the propellant, the aerosol composition may also contain a lubricant and a surfactant, which may be chosen from those lubricants and surfactants known in the art. Other suitable aerosol compositions include surfactant-free or substantially surfactant-free aerosol compositions. The aerosol composition may contain up to about 5% by weight, for example 0.002 to 5%, 0.01 to 3%, 0.015 to 2%, 0.1 to 2%, 0.5 to 2% or 0.5 to 1%, by weight of the active ingredient, based on the weight of the propellant. Where present, the lubricant and surfactant may be in an amount up to 5% and 0.5% respectively by weight of the aerosol composition. The aerosol composition may also contain a co-solvent such as ethanol in an amount up to 30% by weight of the composition, particularly for administration from a pressurised metered dose inhalation device.

[0016] In another embodiment of the invention, the inhalable form is a dry powder, i.e. (A) and/or (B) are present in a dry powder comprising finely divided (A) and/or (B) optionally together with a finely divided pharmaceutically acceptable carrier, which is preferably present and may be one or more materials known as pharmaceutically acceptable carriers, preferably chosen from materials known as carriers in dry powder inhalation compositions, for example saccharides, including monosaccharides, disaccharides, polysaccharides and sugar alcohols such as arabinose, glucose, fructose, ribose, mannose, sucrose, trehalose, lactose, maltose, starches, dextran or mannitol. An especially preferred carrier is lactose. The dry powder may be in capsules of gelatin or plastic, or in blisters, for use in a dry powder inhalation device, preferably in dosage units of (A) and/or (B) together with the carrier in amounts to bring the total weight of powder per capsule to from 5 mg to 50 mg. Alternatively, the dry powder may be contained as a reservoir in a multi-dose dry powder inhalation device.

[0017] In the finely divided particulate form of the medicament, and in the aerosol composition where the active ingredient is present in particulate form, the active ingredient may have an average particle diameter of up to about 10 μm , for example 0.1 to 5 μm , preferably 1 to 5 μm . The solid carrier, where present, generally has a maximum particle diameter up to 300 μm , preferably up to 212 μm , and conveniently has a mean particle diameter of 40 to 100 μm , e.g. 50 to 75 μm . The particle size of the active ingredient, and that of a solid carrier where present in dry powder compositions, can be reduced to the desired level by conventional methods, for example by grinding in an air-jet mill, ball mill or vibrator mill, microprecipitation, spray-drying, lyophilisation or recrystallisation from supercritical media.

[0018] The inhalable medicament may be administered using an inhalation device suitable for the inhalable form, such devices being well known in the art. Accordingly, the invention also provides a pharmaceutical product comprising a medicament or pharmaceutical composition as hereinbefore described in inhalable form as hereinbefore described in association with one or more inhalation devices. In a further aspect, the invention provides an inhalation device, or a pack of two or more inhalation devices, containing a medicament or pharmaceutical composition as hereinbefore described in inhalable form as hereinbefore described.

[0019] Where the inhalable form of the active ingredient is an aerosol composition, the inhalation device may be an aerosol vial provided with a valve adapted to deliver a metered dose, such as 10 to 100 μl , e.g. 25 to 50 μl , of the composition, i.e. a device known as a metered dose inhaler. Suitable such aerosol vials and procedures for containing within them aerosol compositions under pressure are well known to those skilled in the art of inhalation therapy. For example, an aerosol composition may be administered from a coated can, for example as described in EP-A-0642992. Where the inhalable form of the active ingredient is a nebulizable aqueous, organic or aqueous/organic dispersion, the inhalation device may be a known nebulizer, for example a conventional pneumatic nebulizer such as an airjet nebulizer, or an ultrasonic nebulizer, which may contain, for example, from 1 to 50 ml, commonly 1 to 10 ml, of the dispersion; or a hand-held nebulizer, for example an electronically controlled device such as an AERx (ex Aradigm,

US) or a mechanical device such as a RESPIMAT (Boehringer Ingelheim) nebulizer which allows much smaller nebulized volumes, e.g. 10 to 100 μ l, than conventional nebulizers. Where the inhalable form of the active ingredient is the finely divided particulate form, the Inhalation device may be, for example, a dry powder inhalation device adapted to deliver dry powder from a capsule or blister containing a dry powder comprising a dosage unit of (A) and/or (B) or a multidose dry powder inhalation (MDPI) device adapted to deliver, for example, 3-25 mg of dry powder comprising a dosage unit of (A) and/or (B) per actuation. Suitable such dry powder inhalation devices are well known. For example, a suitable device for delivery of dry powder in encapsulated form is that described in US3991761, while a suitable MDPI device is that described in WO97/20589.

[0020] The medicament of the invention is preferably a pharmaceutical composition comprising a mixture of (A) as hereinbefore defined and (B) as hereinbefore defined, preferably together with a pharmaceutically acceptable carrier as hereinbefore described.

[0021] The weight ratio of formoterol, or salt or solvate thereof, to mometasone furoate may be, in general, from 2:1 to 1:2000, for example from 1:1 to 1:1000, from 1:2 to 1:100, or from 1:5 to 1:50. More usually, this ratio is from 1:10 to 1:25, for example from 1:15 to 1:25. The two drugs may be administered separately in the same ratio. Specific examples of this ratio, to the nearest whole number, include 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, 1:20, 1:21, 1:22, 1:23, 1:24 and 1:25. The above weight ratios apply particularly where (A) is formoterol fumarate dihydrate. Thus, since the molecular weights of formoterol fumarate dihydrate and mometasone furoate are 840.9 and 521.4 respectively, the corresponding molar ratios of (A) to (B) may be, in general, from 1.24:1 to 1:3227, for example from 0.62:1 to 1:1613, from 1:3.2 to 1:161, or from 1:8.1 to 1:80.7; more usually from 1:16.1 to 1:40.3, for example from 1:24.2 to 1:40.3; specific examples of the molar ratio being 1:16.1, 1:17.8, 1:19.4, 1:21, 1:22.6, 1:24.2, 1:25.8, 1:27.4, 1:29, 1:30.7, 1:32.3, 1:33.9, 1:35.5, 1:37.1, 1:38.7 and 1:40.3.

[0022] A suitable daily dose of formoterol, or salt or solvate thereof, particularly as formoterol fumarate dihydrate, for inhalation may be from 1 to 72 μ g, for example from 1 to 60 μ g, generally from 3 to 50 μ g, preferably from 6 to 48 μ g, for instance from 6 to 24 μ g. A suitable daily dose of mometasone furoate for inhalation may be from 50 to 2000 μ g, for example from 100 to 2000 μ g, from 100 to 1600 μ g, from 100 to 1000 μ g, or from 100 to 800 μ g, preferably from 200 to 500 μ g, for instance from 200 to 400 μ g. The precise dose used will of course depend on the condition to be treated, the patient and the efficiency of the inhalation device.

[0023] A suitable unit dose of formoterol component (A), particularly as formoterol fumarate dihydrate, may be from 1 to 72 μ g, for example from 1 to 60 μ g, generally from 3 to 48 μ g, preferably from 6 to 36 μ g, especially from 12 to 24 μ g. A suitable unit dose of mometasone furoate (B) may be from 25 μ g to 2000 μ g, for example from 50 μ g to 1000 μ g, preferably from 500 μ g to 800 μ g, more preferably from 100 μ g to 500 μ g, especially from 100 to 400 μ g, e.g. from 200 to 400 μ g. These unit doses may suitably be administered once or twice daily in accordance with the suitable daily dose mentioned hereinbefore. For on demand usage, a dosage unit containing 6 μ g or 12 μ g of (A) and 50 μ g or 100 μ g of mometasone furoate (B) is preferred.

[0024] In one preferred embodiment of the invention, the medicament of the invention is a pharmaceutical composition which is a dry powder in a capsule containing a unit dose of (A) and (B), for example for inhalation from a single capsule inhaler, the capsule suitably containing, where (A) is formoterol fumarate dihydrate, from 3 μ g to 36 μ g of (A), preferably from 6 μ g to 24 μ g of (A), especially from 12 μ g to 24 μ g of (A), and from 25 μ g to 800 μ g, e.g. 25 μ g to 500 μ g or 25 μ g to 400 μ g, of (B), preferably from 50 μ g to 400 μ g of (B), especially from 100 to 400 μ g of (B), together with a pharmaceutically acceptable carrier as hereinbefore described in an amount to bring the total weight of dry powder per capsule to between 5 mg and 50mg, for example 5mg, 10mg, 15mg, 20mg, 25mg, 30mg, 35mg, 40mg, 45mg or 50mg, preferably 20 to 25 mg, especially 25 mg.

[0025] In another preferred embodiment of the invention, the medicament of the invention is a pharmaceutical composition which is a dry powder for administration from a reservoir of a multi-dose dry powder Inhaler adapted to deliver 3mg to 25mg of powder containing a unit dose of (A) and (B) per actuation, for example, where (A) is formoterol fumarate dihydrate, a powder comprising, by weight, 3 to 36 parts, preferably 6 to 24 parts, especially 12 to 24 parts of (A); 25 to 800 parts, e.g. 25 to 500 parts, preferably 50 to 400 parts, especially 100 to 400 parts of (B); and 2164 to 24972 parts, preferably 4164 to 14972 parts, especially 4164 to 9972 parts of a pharmaceutically acceptable carrier as hereinbefore described.

[0026] In accordance with the above, the invention also provides a pharmaceutical kit comprising (A) and (B) as hereinbefore defined in separate unit dosage forms, said forms being suitable for administration of (A) and (B) in effective amounts. Such a kit suitably further comprises one or more Inhalation devices for administration of (A) and (B). For example, the kit may comprise one or more dry powder inhalation devices adapted to deliver dry powder from a capsule, together with capsules containing a dry powder comprising a dosage unit of (A) and capsules containing a dry powder comprising a dosage unit of (B). In another example, the kit may comprise a multidose dry powder inhalation device containing in the reservoir thereof a dry powder comprising (A) and a multidose dry powder inhalation device containing in the reservoir thereof a dry powder comprising (B). In a further example, the kit may comprise a metered dose inhaler containing an aerosol comprising (A) in a propellant and a metered dose inhaler containing

an aerosol comprising (B) in a propellant.

[0027] Treatment of inflammatory or obstructive airways diseases in accordance with the invention may be symptomatic or prophylactic treatment. Inflammatory or obstructive airways diseases to which the present invention is applicable include asthma of whatever type or genesis including both intrinsic (non-allergic) asthma and extrinsic (allergic) asthma. Treatment of asthma is also to be understood as embracing treatment of subjects, e.g. of less than 4 or 5 years of age, exhibiting wheezing symptoms and diagnosed or diagnosable as "wheezy infants", an established patient category of major medical concern and now often identified as incipient or early-phase asthmatics. (For convenience this particular asthmatic condition is referred to as "wheezy-infant syndrome".)

[0028] Prophylactic efficacy in the treatment of asthma will be evidenced by reduced frequency or severity of symptomatic attack, e.g. of acute asthmatic or bronchoconstrictor attack, improvement in lung function or improved airways hyperreactivity. It may further be evidenced by reduced requirement for other, symptomatic therapy, i.e. therapy for or intended to restrict or abort symptomatic attack when it occurs, for example anti-inflammatory (e.g. corticosteroid) or bronchodilatory. Prophylactic benefit in asthma may in particular be apparent in subjects prone to "morning dipping". "Morning dipping" is a recognised asthmatic syndrome, common to a substantial percentage of asthmatics and characterised by asthma attack, e.g. between the hours of about 4 to 6 am, i.e. at a time normally substantially distant from any previously administered symptomatic asthma therapy.

[0029] Other inflammatory or obstructive airways diseases and conditions to which the present invention is applicable include acute lung injury (ALI), adult respiratory distress syndrome (ARDS), chronic obstructive pulmonary, airways or lung disease (COPD, COAD or COLD), including chronic bronchitis and emphysema, bronchiectasis and exacerbation of airways hyperreactivity consequent to other drug therapy, in particular other inhaled drug therapy. Further inflammatory or obstructive airways diseases to which the present invention is applicable include pneumoconiosis (an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts) of whatever type or genesis, including, for example, aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis and byssinosis.

[0030] The invention is illustrated by the following Examples, in which parts are by weight unless stated otherwise.

Example 1 - Aerosol Composition for Metered Dose Inhaler

[0031]

Ingredient	% by weight
Formoterol fumarate dihydrate	0.012
Mometasone furoate	0.250
Ethanol (absolute)	2.500
HFA 227	60.768
HFA134a	36.470

Example 2 - Dry Powder

[0032]

Ingredient	% by weight
Formoterol fumarate dihydrate	0.048
Mometasone furoate	1.000
Lactose monohydrate	98.952

Example 3

[0033] A dry powder suitable for delivery from the reservoir of the multi-dose inhaler described in WO97/20589 is prepared by mixing 12 parts of formoterol fumarate dihydrate which has been ground to a mean particle diameter of 1-5µm in an air-jet mill, 250 parts of mometasone furoate which has been similarly ground to a mean particle diameter of 1-5µm and 4738 parts of lactose monohydrate having a particle diameter below 212µm.

EP 1 325 765 A1

Examples 4 - 92

[0034] Example 3 is repeated, but using the amounts of the ingredients shown in the table below in place of the amounts used in that Example :

5

10

15

20

25

30

35

40

45

50

55

Example	Formoterol Fumarate Dihydrate (Parts)	Mometasone Furoate (Parts)	Lactose Monohydrate (Parts)
4	12	50	4938
5	12	100	4888
6	12	150	4838
7	12	200	4788
8	6	50	4944
9	6	100	4894
10	6	150	4844
11	6	200	4794
12	6	250	4744
13	18	50	4932
14	18	100	4882
15	18	150	4832
16	18	200	4782
17	18	250	4732
18	24	50	4926
19	24	100	4876
20	24	150	4826
21	24	200	4776
22	24	250	4726
23	30	50	4920
24	30	100	4870
25	30	150	4820
26	30	200	4770
27	30	250	4720
28	36	50	4914
29	36	100	4864
30	36	150	4814
31	36	200	4764
32	36	250	4714
33	6	50	9944
34	6	100	9894
35	6	150	9844
36	6	200	9794
37	6	250	9744
38	12	50	9938

EP 1 325 765 A1

(continued)

	Example	Formoterol Fumarate Dihydrate (Parts)	Mometasone Furoate (Parts)	Lactose Monohydrate (Parts)
5	39	12	100	9888
	40	12	150	9838
	41	12	200	9788
10	42	12	250	9738
	43	18	50	9932
	44	18	100	9882
	45	18	150	9832
15	46	18	200	9782
	47	18	250	9732
	48	24	50	9926
20	49	24	100	9876
	50	24	150	9826
	51	24	200	9776
	52	24	250	9726
25	53	30	50	9920
	54	30	100	9870
	55	30	150	9820
30	56	30	200	9770
	57	30	250	9720
	58	36	50	9914
	59	36	100	9864
35	60	36	150	9814
	61	36	200	9764
	62	36	250	9714
40	63	6	50	14944
	64	6	100	14894
	65	6	150	14844
	66	6	200	14794
45	67	6	250	14744
	68	12	50	14938
	69	12	100	14888
50	70	12	150	14838
	71	12	200	14788
	72	12	250	14738
	73	18	50	14932
55	74	18	100	14882
	75	18	150	14832

EP 1 325 765 A1

(continued)

Example	Formoterol Fumarate Dihydrate (Parts)	Mometasone Furoate (Parts)	Lactose Monohydrate (Parts)
76	18	200	14782
77	18	250	14732
78	24	50	14926
79	24	100	14876
80	24	150	14826
81	24	200	14776
82	24	250	14726
83	30	50	14920
84	30	100	14870
85	30	150	14820
86	30	200	14770
87	30	250	14720
88	36	50	14914
89	36	100	14864
90	36	150	14814
91	36	200	14764
92	36	250	14714

Example 93

[0035] Gelatin capsules suitable for use in a capsule inhaler such as that described in US3991761 are prepared, each capsule containing a dry powder obtained by mixing 12µg of formoterol fumarate dihydrate which has been ground to a mean particle diameter of 1 to 5µm in an air jet mill, 250µg of mometasone furoate which has been similarly ground to a mean particle diameter of 1 to 5µm and 24738µg of lactose monohydrate having a particle diameter below 212µm.

Examples 94 - 152

[0036] Example 93 is repeated, but using the amounts of the ingredients shown in the table below in place of the amounts used in that Example :

Example	Formoterol Fumarate Dihydrate (Parts)	Mometasone Furoate (Parts)	Lactose Monohydrate (Parts)
94	12	50	24938
95	12	100	24888
96	12	150	24838
97	12	200	24788
98	6	50	24944
99	6	100	24894
100	6	150	24844
101	6	200	24794
102	6	250	24744

EP 1 325 765 A1

(continued)

Example	Formoterol Fumarate Dihydrate (Parts)	Mometasone Furoate (Parts)	Lactose Monohydrate (Parts)
5	103	18	50
			24932
	104	18	100
			24882
	105	18	150
			24832
10	106	18	200
			24782
	107	18	250
			24732
	108	24	50
			24926
	109	24	100
			24876
15	110	24	150
			24826
	111	24	200
			24776
	112	24	250
			24726
20	113	30	50
			24920
	114	30	100
			24870
	115	30	150
			24820
	116	30	200
			24770
25	117	30	250
			24720
	118	36	50
			24914
	119	36	100
			24864
30	120	36	150
			24814
	121	36	200
			24764
	122	36	250
			24714
	123	6	50
			19944
35	124	6	100
			19894
	125	6	150
			19844
	126	6	200
			19794
40	127	6	250
			19744
	128	12	50
			19938
	129	12	100
			19888
	130	12	150
			19838
45	131	12	200
			19788
	132	12	250
			19738
	133	18	50
			19932
50	134	18	100
			19882
	135	18	150
			19832
	136	18	200
			19782
	137	18	250
			19732
55	138	24	50
			19926
	139	24	100
			19876

EP 1 325 765 A1

(continued)

Example	Formoterol Fumarate Dihydrate (Parts)	Mometasone Furoate (Parts)	Lactose Monohydrate (Parts)
140	24	150	19826
141	24	200	19776
142	24	250	19726
143	30	50	19920
144	30	100	19870
145	30	150	19820
146	30	200	19770
147	30	250	19720
148	36	50	19914
149	36	100	19864
150	36	150	19814
151	36	200	19764
152	36	250	19714

Examples 153 - 176

[0037] Example 3 is repeated, but using the amounts of the ingredients shown in the table below in place of the amounts used in that Example:

Example	Formoterol Fumarate Dihydrate (Parts)	Mometasone Furoate (Parts)	Lactose Monohydrate (Parts)
153	6	25	2969
154	6	50	2944
155	6	100	2894
156	6	150	2844
157	6	200	2794
158	6	250	2744
159	12	25	2963
160	12	50	2938
161	12	100	2888
162	12	150	2838
163	12	200	2788
164	12	250	2738
165	12	300	2638
166	12	350	2588
167	12	400	2538
168	24	25	2951
169	24	50	2926
170	24	100	2876

EP 1 325 765 A1

(continued)

Example	Formoterol Fumarate Dihydrate (Parts)	Mometasone Furoate (Parts)	Lactose Monohydrate (Parts)
171	24	150	2826
172	24	200	2776
173	24	250	2726
174	24	300	2676
175	24	350	2626
176	24	400	2576

Examples 177-281

[0038] Example 93 is repeated, but using the amounts of the ingredients shown in the table below in place of the amounts used in that Example:

Example	Formoterol Fumarate Dihydrate (µg)	Mometasone Furoate (µg)	Lactose Monohydrate (µg)
177	6	25	14969
178	6	50	14944
179	6	100	14894
180	6	150	14844
181	6	200	14794
182	6	250	14744
183	6	300	14694
184	6	350	14644
185	6	400	14594
186	12	25	14963
187	12	50	14938
188	12	100	14888
189	12	150	14838
190	12	200	14788
191	12	250	14738
192	12	300	14688
193	12	350	14638
194	12	400	14588
195	12	500	14488
196	24	25	14951
197	24	50	14926
198	24	100	14876
199	24	150	14826
200	24	200	13876
201	24	250	13826
202	24	300	13776

EP 1 325 765 A1

(continued)

	Example	Formoterol Fumarate Dihydrate (µg)	Mometasone Furoate (µg)	Lactose Monohydrate (µg)
5	203	6	25	9969
	204	6	50	9944
	205	6	100	9894
	206	6	150	9844
10	207	6	200	9794
	208	6	250	9744
	209	6	300	9694
15	210	12	25	9963
	211	12	50	9938
	212	12	100	9888
	213	12	150	9838
20	214	12	200	9788
	215	12	250	9738
	216	12	300	9688
25	217	12	400	9588
	218	12	500	9488
	219	24	25	9951
	220	24	50	9926
30	221	24	100	9876
	222	24	150	9826
	223	24	200	9776
35	224	24	250	9726
	225	24	300	9676
	226	24	400	9576
	227	24	500	9476
40	228	6	25	4969
	229	6	50	4944
	230	6	100	4894
45	231	6	150	4844
	232	6	200	4794
	233	6	250	4744
	234	6	300	4694
50	235	6	400	4594
	236	6	500	4494
	237	12	25	4963
55	238	12	50	4938
	239	12	100	4888
	240	12	200	4788

EP 1 325 765 A1

(continued)

	Example	Formoterol Fumarate Dihydrate (μg)	Mometasone Furoate (μg)	Lactose Monohydrate (μg)
5	241	12	300	4688
	242	12	400	4588
	243	12	500	4488
	244	12	25	24963
10	245	12	300	24688
	246	12	400	24588
	247	12	500	24488
15	248	12	25	19963
	249	12	300	19688
	250	12	400	19588
	251	12	500	19488
20	252	6	600	4394
	253	6	800	4194
	254	12	600	4388
25	255	12	800	4188
	256	24	600	4376
	257	24	800	4176
	258	6	600	9394
30	259	6	800	9194
	260	12	600	9388
	261	12	800	9188
35	262	24	600	9376
	263	24	800	9176
	264	6	600	14394
	265	6	800	14194
40	266	12	600	14388
	267	12	800	14188
	268	24	600	14376
45	269	24	800	14176
	270	6	600	19394
	271	6	800	19194
	272	12	600	19388
50	273	12	800	19188
	274	24	600	19376
	275	24	800	19176
55	276	6	600	24394
	277	6	800	24194
	278	12	600	24388

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 03 00 3950

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

08-05-2003

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9841193	A	24-09-1998	AU 741783 B2	06-12-2001
			AU 6537898 A	12-10-1998
			CN 1257423 T	21-06-2000
			EP 0969816 A1	12-01-2000
			HU 0002029 A2	28-11-2000
			JP 2000510478 T	15-08-2000
			NO 994519 A	19-11-1999
			NZ 337443 A	27-04-2001
			PL 335742 A1	08-05-2000
			SK 128099 A3	12-06-2000
			WO 9841193 A1	24-09-1998
			ZA 9802254 A	17-09-1998
US 6030604	A	29-02-2000	US 6287540 B1	11-09-2001
			AU 731192 B2	29-03-2001
			AU 5785998 A	07-08-1998
			BR 9811249 A	05-09-2000
			CZ 9902557 A3	13-10-1999
			EE 9900295 A	15-02-2000
			EP 1007017 A1	14-06-2000
			HU 0000714 A2	28-08-2000
			JP 2001508793 T	03-07-2001
			NO 993539 A	20-09-1999
			NZ 336594 A	26-01-2001
			PL 334527 A1	28-02-2000
			RU 2194497 C2	20-12-2002
			WO 9831352 A1	23-07-1998
			SK 95999 A3	18-01-2000
			TR 9901690 T2	21-09-1999
			ZA 9800078 A	20-07-1998
			US 5980949 A	09-11-1999
			US 5983956 A	16-11-1999
WO 03020253	A	13-03-2003	WO 03020253 A2	13-03-2003
WO 0015234	A	23-03-2000	AU 6018999 A	03-04-2000
			WO 0015234 A1	23-03-2000
WO 9505805	A	02-03-1995	AT 199828 T	15-04-2001
			AU 681186 B2	21-08-1997
			AU 7626494 A	21-03-1995
			BR 9407320 A	16-04-1996
			CN 1133004 A ,B	09-10-1996
			CN 1195523 A ,B	14-10-1998
			CZ 9600544 A3	15-05-1996
			DE 69426934 D1	26-04-2001

EPO FORM P468

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 03 00 3950

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

08-05-2003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9505805 A		DE 69426934 T2	13-09-2001
		DK 717616 T3	11-06-2001
		EE 3203 B1	16-08-1999
		EG 20779 A	29-02-2000
		EP 0717616 A1	26-06-1996
		ES 2156158 T3	16-06-2001
		FI 960869 A	26-02-1996
		GR 3036106 T3	28-09-2001
		HU 74000 A2	28-10-1996
		JP 2978247 B2	15-11-1999
		JP 9501930 T	25-02-1997
		NO 960744 A	23-02-1996
		NZ 273090 A	24-06-1997
		PL 313142 A1	10-06-1996
		PT 717616 T	30-08-2001
		RU 2148992 C1	20-05-2000
		WO 9505805 A1	02-03-1995
		SG 47760 A1	17-04-1998
		SK 23496 A3	05-02-1997
		US 5709884 A	20-01-1998
		US 5637620 A	10-06-1997
		US 5874063 A	23-02-1999
		ZA 9405675 A	29-04-1996
WO 9918971 A	22-04-1999	AT 216244 T	15-05-2002
		AU 9674398 A	03-05-1999
		CA 2305256 A1	22-04-1999
		DE 69804998 D1	23-05-2002
		DE 69804998 T2	12-12-2002
		EP 1033991 A1	13-09-2000
		ES 2172217 T3	16-09-2002
		JP 2001519397 T	23-10-2001
		WO 9918971 A1	22-04-1999
WO 9834595 A	13-08-1998	AT 219355 T	15-07-2002
		AU 718967 B2	04-05-2000
		AU 5649698 A	26-08-1998
		WO 9834595 A1	13-08-1998
		DE 59804534 D1	25-07-2002
		DK 1014943 T3	14-10-2002
		EP 1014943 A1	05-07-2000
		ES 2178817 T3	01-01-2003
		JP 2001511160 T	07-08-2001
		NO 993773 A	04-10-1999
		NZ 337065 A	23-02-2001
		PT 1014943 T	29-11-2002

EPO FORM P4589

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.